Selank vs Semax: Russian Nootropic Peptides Head-to-Head

Two of the most-discussed short regulatory peptides of Russian-pharmacology origin, compared on the same axes. Mechanisms, intranasal pharmacokinetics, the actual clinical evidence base, and where the popular nootropic framing exceeds what controlled human data supports.

Selank and Semax occupy an unusual position in the peptide conversation. Both originated in the Soviet and post-Soviet Russian academic-pharmacology system in the 1980s and 1990s, both were derived from endogenous peptides by replacing or extending a short bioactive fragment with stabilizing residues, and both are administered intranasally for central nervous system effects. In Russia, both have actual marketing authorization for specific clinical indications — Semax (Семакс) is registered for cerebrovascular and neurological use, and Selank (Селанк) is registered as an anxiolytic. Outside Russia, neither has FDA approval or any equivalent Western regulatory status, and almost all use in the broader nootropic community happens through unregulated supply.

This article is a side-by-side mechanism-and-evidence comparison of the two molecules. The goal is not to declare a winner but to give a clear picture of what is actually known, what is plausibly inferred, and what the popular framing tends to overstate. For the broader frame on how to read peptide evidence at all, see our Peptide Safety Guide.

What each molecule actually is

Semax

Semax is a heptapeptide whose sequence is derived from a fragment of adrenocorticotropic hormone (ACTH) — specifically, ACTH(4–7) extended with a Pro-Gly-Pro tripeptide tail. The Pro-Gly-Pro extension is the engineering trick that does most of the work: it dramatically slows enzymatic degradation of the fragment, allowing measurable central nervous system exposure after intranasal administration. The parent ACTH(4–7) fragment had been known since the 1970s to have neurotropic effects without the steroidogenic effects of full ACTH, but it was too short-lived to be useful as a drug. Semax is essentially the stable, deliverable form of that fragment.

Selank

Selank is also a heptapeptide, derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with the same Pro-Gly-Pro stabilizing tail added. Tuftsin itself is a fragment of the IgG heavy chain with documented effects on macrophage activation and immune signaling. As with Semax, the Pro-Gly-Pro extension was added to extend the half-life of the bioactive parent fragment enough to make intranasal delivery viable. Selank therefore inherits some of tuftsin's immunomodulatory biology while displaying the central anxiolytic profile that motivated its clinical development.

Semax sequence

Met-Glu-His-Phe-Pro-Gly-Pro

Semax parent

ACTH(4–7) fragment

Selank sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Selank parent

Tuftsin (Thr-Lys-Pro-Arg)

Shared design trick

Pro-Gly-Pro C-terminal extension for peptidase resistance

Route

Intranasal drops (both)

US regulatory status

Neither is FDA-approved

Russian regulatory status

Both registered; different indications

Note: The serious clinical evidence base for both peptides is almost entirely Russian-language and clusters in a relatively small number of research groups. This is a real evidence base — not nothing — but it has structural limitations that any honest comparison has to acknowledge upfront.

Mechanism: where the two diverge

Semax: BDNF, dopaminergic tone, and the nootropic story

The most-cited mechanistic finding for Semax is that it appears to increase brain-derived neurotrophic factor (BDNF) expression in relevant brain regions, particularly in animal models of cerebral ischemia. BDNF is a major neurotrophin that supports neuronal survival, synaptic plasticity, and long-term potentiation, and its upregulation is part of the rationale for using Semax in stroke recovery contexts. Beyond BDNF, animal studies have reported effects on dopaminergic and serotonergic tone, on enkephalin metabolism, and on the activity of brain peptidases. The picture is that of a small molecule that nudges several modulatory neurochemical systems at once, rather than acting through a single dominant receptor.

The popular nootropic framing of Semax tends to compress this into "increases BDNF and focus." The mechanistic part is loosely consistent with the literature. The subjective-effect part is much less well established in controlled human studies, especially in healthy subjects without underlying neurological deficit.

Selank: GABAergic modulation and the anxiolytic story

Selank's most-cited mechanistic findings cluster around modulation of GABAergic neurotransmission — specifically, effects on GABA-A receptor expression and on brain enkephalin systems that interact with anxiety circuits. The anxiolytic profile in animal models is reasonably robust across several test paradigms, and Russian controlled trials in generalized anxiety disorder have reported reductions in anxiety scores that are described as comparable to short courses of benzodiazepines without the sedation and dependence profile. There is also reported modulation of cytokine balance (an inheritance from the tuftsin lineage) that is sometimes framed as a peripheral immune-axis contribution to the anxiolytic effect.

Again, the mechanistic outline is grounded in real biology. The translation from the Russian clinical context to nootropic-community claims of "calm focus without side effects" is a much larger leap than the underlying papers themselves justify.

Intranasal pharmacokinetics: the shared delivery question

Both Semax and Selank are administered as intranasal drops, and the pharmacokinetic argument for this route is essentially the same in both cases. Short peptides are degraded almost instantly in the gastrointestinal tract, and they cross the blood-brain barrier poorly when administered systemically. Intranasal delivery exploits two facts: a fraction of the dose is absorbed across nasal mucosa into systemic circulation, and a smaller but pharmacologically relevant fraction is thought to reach the central nervous system more directly via olfactory and trigeminal pathways. The Pro-Gly-Pro tail extends the time window during which intact peptide is available for either route.

The honest acknowledgment is that the absolute bioavailability of intact Semax or Selank reaching specific CNS targets after a given intranasal dose is not characterized to modern Western pharmacokinetic standards. The intranasal route works in animal models and in the clinical contexts where it has been used, but anyone telling you the exact percentage that crosses to brain is overstating what the public literature establishes.

Head-to-head: the comparison table

What the evidence actually supports — and what it does not

What is reasonably supported

• Both molecules are biologically active. The mechanistic findings — BDNF upregulation for Semax, GABAergic modulation for Selank — are not invented and not implausible.
• Both have a registered Russian clinical role. Semax in cerebrovascular and cognitive-deficit contexts, Selank in anxiety. Within those contexts, modest effect sizes are reported in controlled trials.
• Both have a clean acute safety record at the doses studied in those trials, over the relatively short durations studied.
• Intranasal delivery is the right route. The peptide stability and BBB arguments do hold; this is not snake oil pharmacology.

What is overclaimed

• "Reliable nootropic enhancement in healthy adults." The Russian clinical evidence is in populations with deficits — stroke patients, anxious patients — not in healthy high-performers. Generalizing trial effects to healthy enhancement is unsupported.
• "Equivalent to benzodiazepines / SSRIs without side effects." Comparison claims are made in some Russian write-ups but at small sample sizes and short durations. The "no side effects" half of the claim is not a long-term-data conclusion.
• "Validated in Western medicine." Neither molecule has FDA approval, EMA approval, or large Western RCTs supporting any indication. The Russian evidence is real but not interchangeable with Western regulatory-grade evidence.
• "Permanently rewires the brain via BDNF." Acute BDNF modulation is documented; long-term structural neuroplasticity claims rest on extrapolation.

Side effects and the structural unknowns

At the doses studied in Russian clinical work, both Semax and Selank have generally clean acute side-effect profiles. Reported adverse effects are mild and infrequent — most often local nasal irritation, occasional transient headache, occasional sleep changes (more often reported with Semax than Selank, consistent with its more activating profile). Severe adverse events in the published trials are rare.

The honest caveats are structural. First, sample sizes are small by Western standards, so rare serious adverse events would not be reliably detected. Second, treatment durations in trials are usually weeks to months, not years, so chronic-use safety is essentially uncharacterized. Third, supply outside Russia is unregulated; the molecule sold as Selank or Semax on the gray market may not be what the label claims, and contamination with bacterial endotoxins from poor sterile process is a non-trivial risk for any intranasal product. The framework for thinking about this kind of supply-side risk is covered in How to Evaluate Peptide Quality.

The regulatory frame outside Russia

Neither Semax nor Selank is FDA-approved in the United States. Neither has an established 503A or 503B compounding pathway of the kind that has shaped the regulatory conversation around peptides like BPC-157 and the GLP-1 family. For the broader regulatory context — and why FDA treatment of "peptides" is more nuanced than a single binary category — see FDA Peptide Status 2026. Without an approved indication, any US use of either molecule is by definition outside the regulatory system, and the supply chain reflects that.

How they actually compare in practice

If a single sentence has to summarize the practical comparison: Semax is the more activating molecule with a clinical heritage in cerebrovascular and cognitive-deficit indications and a mechanistic story centered on BDNF and monoaminergic modulation, while Selank is the more calming molecule with a clinical heritage in anxiety and a mechanistic story centered on GABAergic and immune-axis modulation. Both are short Russian-origin regulatory peptides delivered intranasally, both have a real but Russian-language clinical evidence base, and both sit entirely outside the FDA system in the United States.

The choice between them, in the popular framing, tends to be presented as "Semax for focus, Selank for calm." This framing is loosely defensible as a description of the activation profile direction but it is not the same as saying either molecule is a validated nootropic for healthy use. The Russian clinical evidence is in patient populations with measurable deficits, and that is where the effect sizes have been reported. Generalizing the same effect sizes to optimization in healthy adults is the leap that the underlying papers do not make.

Where this leaves the careful reader

Selank and Semax are interesting molecules precisely because they sit in the middle of the evidence spectrum. They are not unstudied — both have real animal pharmacology and real (if geographically concentrated) clinical evidence. They are not FDA-approved either, which means the Western mainstream pharmacology and pharmacovigilance machinery has not been applied to them in the way it has to, say, the GLP-1 receptor agonists discussed in our Semaglutide vs Tirzepatide comparison.

The intellectually honest position is that both molecules are plausibly biologically active, that the Russian clinical context supports modest effect claims in specific patient populations, that the nootropic-community claims for healthy enhancement substantially outrun that evidence, and that long-term safety in chronic out-of-indication use is essentially uncharacterized. This is not the same as saying "they don't work" and it is not the same as saying "they're safe and effective." It is the more boring middle position that the actual literature actually supports.

The honest comparison summary in one paragraph

Semax and Selank are sibling molecules — both Russian heptapeptides built on the same Pro-Gly-Pro stabilization design, both administered intranasally, both with real but Russian-language clinical evidence in specific patient populations (stroke and cognitive deficit for Semax, anxiety for Selank), and both with mechanistic stories that are loosely consistent with that evidence (BDNF and monoaminergic tone for Semax, GABAergic and immune-axis modulation for Selank). They are not interchangeable nootropic options for healthy enhancement, they are not Western-regulated drugs, and their long-term safety profile in chronic use is not established. Within those caveats, they are among the more interesting short peptides in the modern conversation, and they reward being thought about carefully rather than as members of a generic "Russian peptide" category.

Further reading on PeptideAdvance

• Selank peptide page
• Semax peptide page
• Selank glossary entry
• Semax glossary entry
• Nootropic glossary entry
• BDNF glossary entry
• Peptide Safety Guide
• How to Evaluate Peptide Quality
• FDA Peptide Status 2026